Gene

HDAC2

histone deacetylase 2

Explore in graph →CI-GENE-00004239HGNC:4853 ENSG00000196591 NCBI 3066 CIViC Approved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HDAC2 Expression1
Abexinostat + PazopanibCombination	Renal Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	5	submitted	EID7057 In this phase Ib study (NCT01543763), the histone deacetylase (HDAC) inhibitor abexinostat was used in combination with the multi-tyrosine kinase inhibitor pazopanib to evaluate the effect of abexinos… (full text at CIViC) PMID 28221861 · Aggarwal et al., 2017 · Open in CIViC	civic
HDAC2 Overexpression1
Mocetinostat	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	4	submitted	EID9130

Cohorts

Alteration frequency by cohort (3)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved3 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Cholangiocarcinoma (National University of Singapore, Nat Genet 2012) chol_nus_2012	Cholangiocarcinoma	Ssm	1	8

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.